Inter-rater reliability of modified hand mobility in scleroderma test.
Nurten Gizem Tore1, Fulden Sari1, Devrim Can Sarac1
1Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Gazi University, Ankara, Turkey.
International Journal of Rheumatic Diseases
|November 21, 2019
Summary
The modified hand mobility in scleroderma (mHAMIS) test shows excellent inter-rater reliability for assessing hand mobility in systemic sclerosis patients. This finding supports its unbiased use in clinical trials for SSc hand mobility assessment.
Area of Science:
- Rheumatology
- Autoimmune Diseases
- Physical Therapy
Background:
- Systemic sclerosis (SSc) is a chronic autoimmune disease affecting collagen production, microvasculature, and causing fibrosis.
- Hand involvement, characterized by skin thickening and reduced mobility, is common in SSc progression.
- Accurate assessment of hand mobility is crucial for managing SSc patients.
Purpose of the Study:
- To evaluate the inter-rater reliability of the modified hand mobility in scleroderma (mHAMIS) test.
- To determine if the mHAMIS test provides consistent measurements between different examiners.
- To validate the mHAMIS test for use in clinical research and practice for SSc.
Main Methods:
- Twenty-five female SSc patients were assessed by two physiotherapists with varying experience levels.
- Exclusion criteria included finger flexion contractures or recent hand surgery.
- Inter-rater reliability was quantified using intra-class correlation coefficients (ICCs).
Main Results:
- The mHAMIS test demonstrated excellent inter-rater reliability for both dominant (ICC=0.92) and non-dominant hands (ICC=0.93).
- High ICC values indicate strong agreement between the two physiotherapists' assessments.
- The results suggest the mHAMIS test is a reliable tool for measuring hand mobility in SSc.
Conclusions:
- The mHAMIS test exhibits excellent inter-rater reliability.
- This study validates the mHAMIS test as a dependable instrument for assessing hand mobility in systemic sclerosis.
- The findings support the use of the mHAMIS test in clinical trials without introducing examiner bias.


